Chandler Robinson

Company: Monopar Therapeutics

Job title: CEO

Seminars:

uPAR: A Promising Novel Radiopharmaceutical Target for Solid Tumors 9:30 am

Revealing why uPAR is a promising radiopharma target and what characteristics make it particularly appealing Sharing the strategy that went into creating Monopar’s targeting agent against uPAR Optimizing biodistribution preclinically and how that translatedRead more

day: Conference Day One